Novo Nordisk to showcase Wegovy data at obesity meet
Key Summary Novo Nordisk to unveil major obesity research at the European Congress, including new Wegovy data. Next-gen…
Novo Nordisk’s CagriSema Data Locked as Pipeline Hopes Wrestle With a 50% Stock Wipeout
Novo Nordisk locks Phase 3 data for CagriSema vs Lilly’s Tirzepatid in diabetes, with shares at half their…
Novo Nordisk’s new weight loss treatment inferior to tirzepatide
Novo Nordisk’s latest weight loss treatment, CagriSema, did not meet the primary endpoint of showing non-inferiority compared to…
Novo Nordisk’s triple agonist delivers up to 19.7% weight loss
Novo Nordisk’s triple agonist UBT251 delivered a mean weight loss of 19.7% after 24 weeks in a Phase…
CagriSema Setback Tests Novo Nordisk Obesity Ambitions And Growth Story
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
Novo and Chinese partner report strong weight loss results
Novo Nordisk and China’s United Laboratories International Holdings have announced promising results from a clinical trial of a…
CagriSema Setback Tests Novo Nordisk Obesity Ambitions And Growth Story
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
Novo Nordisk’s CagriSema trial deals blow in obesity drug battle with Eli Lilly
By Stine Jacobsen and Maggie Fick COPENHAGEN, Feb 23 (Reuters) – Novo Nordisk’s next-generation obesity drug CagriSema underperformed…
Novo Nordisk’s CagriSema study shows 20 percent weight loss, but doesn’t beat tirzepatide
Novo Nordisk today announced headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE…
Novo Nordisk shares fall as Lilly stock climbs
Shares of Novo Nordisk plunged 15% on Monday after the company announced that its next-generation obesity drug failed…